文献速递血液净化与透析

接受高效抗逆转录病毒治疗的肾衰竭患者腹膜透析流出液中检出人类免疫缺陷病毒1型核糖核酸

Detection of human immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on highly active antiretroviral therapy.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该研究前瞻性纳入58例接受高效抗逆转录病毒治疗(HAART)的HIV阳性终末期肾病患者,在置管后三个时间点检测腹膜透析流出液和血浆中的HIV-1 RNA。结果显示流出液中HIV-1 RNA检出率为19%–26.3%,部分样本血浆未检出而流出液检出,血浆HIV-1检出、体重指数、血清白蛋白和HAART方案与流出液检出显著相关。

要点

  • CAPD流出液中可检出HIV-1 RNA,检出率19%–26.3%。
  • 部分样本流出液检出而配对血浆未检出,提示局部 sanctuary 可能。
  • 血浆HIV-1检出、BMI、血清白蛋白和HAART方案与流出液检出相关。

核心结论

  • 即使血浆病毒载量被抑制,HIV颗粒仍以可检测量脱落到CAPD流出液中,提示可能存在局部sanctuary site及接受完整HAART的HIV阳性CAPD患者具有潜在传染性。

研究设计与样本

  • 前瞻性研究,纳入2012年9月至2015年2月间置入Tenckhoff导管的58例接受HAART的HIV阳性终末期肾病患者,随访18个月。
  • 在置管后第45±37天、第200±19天和第377±13天常规门诊随访时,采集 functioning CAPD导管流出液和血浆样本。
  • 所有标本储存于-20°C,每批用Roche定量HIV-1聚合酶链反应检测HIV-1颗粒。
  • 采用聚类 logistic 回归检验CAPD流出液中HIV-1检出的独立预测因素。

主要发现

  • CAPD流出液中HIV-1 RNA超过20拷贝/mL检测限的检出率:第一批19%,第二批26.3%,第三批20%。
  • 流出液检出HIV-1 RNA而配对血浆未检出的比例:第一批3.4%,第二批5.3%,第三批10%。
  • 血浆样本HIV-1检出与流出液HIV-1检出显著相关(比值比3.94;95%置信区间1.14–13.55;P=0.030)。
  • 体重指数、血清白蛋白和HAART方案与CAPD流出液中HIV-1检出显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the shedding of human immunodeficiency virus (HIV)-1 particles into continuous ambulatory peritoneal dialysis (CAPD) effluents of HIV-positive patients with end-stage renal disease (ESRD). METHODS: A total of 58 HIV-positive patients with ESRD on highly active antiretroviral therapy (HAART) who had Tenckhoff catheters inserted between September 2012 and February 2015 were prospectively reviewed and followed for 18 months. Peritoneal dialysis (PD) effluent samples from functioning CAPD catheters and plasma samples were obtained at three points during regular clinic visits on days 45 ± 37, 200 ± 19 and 377 ± 13 after catheter insertion. All specimens were stored at -20°C, and each batch was analysed by Roche quantitative HIV-1 polymerase chain reaction assay to detect HIV-1 particles. Clustered logistic regression was used to test for independent predictors of HIV-1 detection in CAPD effluents. RESULTS: HIV-1 RNA above 20 copies/mL assay limit was detectable in 19% (first batch), 26.3% (second batch) and 20% (third batch) of PD effluent specimens. HIV-1 RNA was detectable in PD fluid, without corresponding detection in the paired plasma in 3.4% (first batch), 5.3% (second batch) and 10% (third batch) of samples. Detection of HIV-1 in plasma sample (odds ratios 3.94; 95% confidence interval 1.14-13.55; P = 0.030), body mass index, serum albumin and HAART regimen were found to be significantly associated with HIV-1 detection in PD effluents. CONCLUSIONS: HIV particles are shed in detectable amounts into CAPD effluents even in patients with suppressed plasma viral load, raising concerns of a localized sanctuary site and potential infectivity of HIV-positive CAPD patients on a full complement of HAART.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ndlovu KC, Sibanda W, Assounga A, et al. Detection of human immunodeficiency virus-1 ribonucleic acid in the peritoneal effluent of renal failure patients on highly active antiretroviral therapy. Nephrol Dial Transplant. 2017. PMID: 28339647. doi:10.1093/ndt/gfx001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。